Skip to main content
Top
Published in: Archives of Virology 10/2014

01-10-2014 | Original Article

A vesicular stomatitis pseudovirus expressing the surface glycoproteins of influenza A virus

Authors: S. V. Cheresiz, A. A. Kononova, Yu. V. Razumova, T. S. Dubich, A. A. Chepurnov, A. A. Kushch, R. Davey, A. G. Pokrovsky

Published in: Archives of Virology | Issue 10/2014

Login to get access

Abstract

Pseudotyped viruses bearing the glycoprotein(s) of a donor virus over the nucleocapsid core of a surrogate virus are widely used as safe substitutes for infectious virus in virology studies. Retroviral particles pseudotyped with influenza A virus glycoproteins have been used recently for the study of influenza hemagglutinin and neuraminidase-dependent processes. Here, we report the development of vesicular-stomatitis-virus-based pseudotypes bearing the glycoproteins of influenza A virus. We show that pseudotypes bearing the hemagglutinin and neuraminidase of H5N1 influenza A virus mimic the wild-type virus in neutralization assays and sensitivity to entry inhibitors. We demonstrate the requirement of NA for the infectivity of pseudotypes and show that viruses obtained with different NA proteins are significantly different in their transduction activities. Inhibition studies with oseltamivir carboxylate show that neuraminidase activity is required for pseudovirus production, but not for the infection of target cells with H5N1-VSV pseudovirus. The HA-NA-VSV pseudoviruses have high transduction titers and better stability than the previously reported retroviral pseudotypes and can replace live influenza virus in the development of neutralization assays, screening of potential antivirals, and the study of different HA/NA reassortants.
Literature
1.
2.
go back to reference Su Y, Zhu X, Wang Y, Wu M, Tien P (2008) Evaluation of Glu11 and Gly8 of the H5N1 influenza hemagglutinin fusion peptide in membrane fusion using pseudotype virus and reverse genetics. Arch Virol 153:247–257. doi:10.1007/s00705-007-1088-9 PubMedCrossRef Su Y, Zhu X, Wang Y, Wu M, Tien P (2008) Evaluation of Glu11 and Gly8 of the H5N1 influenza hemagglutinin fusion peptide in membrane fusion using pseudotype virus and reverse genetics. Arch Virol 153:247–257. doi:10.​1007/​s00705-007-1088-9 PubMedCrossRef
3.
go back to reference Wang SY, Su CY, Lin M, Huang SY, Huang WI, Wang CC, Wu YT, Cheng TJ, Yu HM, Ren CT, Wu CY, Wang CH, Cheng YS (2009) HA-pseudotyped retroviral vectors for influenza antagonist screening. J Biomol Screen 14:294–302. doi:10.1177/1087057108330786 PubMedCrossRef Wang SY, Su CY, Lin M, Huang SY, Huang WI, Wang CC, Wu YT, Cheng TJ, Yu HM, Ren CT, Wu CY, Wang CH, Cheng YS (2009) HA-pseudotyped retroviral vectors for influenza antagonist screening. J Biomol Screen 14:294–302. doi:10.​1177/​1087057108330786​ PubMedCrossRef
4.
go back to reference Wang W, Butler EN, Veguilla V, Vassell R, Thomas JT, Moos M Jr, Ye Z (2008) Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Methods 153:111–119. doi:10.1016/j.jviromet.2008.07.015 PubMedCrossRef Wang W, Butler EN, Veguilla V, Vassell R, Thomas JT, Moos M Jr, Ye Z (2008) Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J Virol Methods 153:111–119. doi:10.​1016/​j.​jviromet.​2008.​07.​015 PubMedCrossRef
5.
go back to reference Zhang F, Wu J, Xu C, Lin X, Zhao H, Lu J, Zhang Y, Lu J, Zhang X, Ma J, Shu Y, Lou Y, Gao J, Wang Y (2011) Infectivity of pseudotyped particles pairing hemagglutinin of highly pathogenic avian influenza a H5N1 virus with neuraminidases of the 2009 pandemic H1N1 and a seasonal H3N2. J Bioterr Biodef 2(1):1–6. doi:10.4172/2157-2526.1000104 CrossRef Zhang F, Wu J, Xu C, Lin X, Zhao H, Lu J, Zhang Y, Lu J, Zhang X, Ma J, Shu Y, Lou Y, Gao J, Wang Y (2011) Infectivity of pseudotyped particles pairing hemagglutinin of highly pathogenic avian influenza a H5N1 virus with neuraminidases of the 2009 pandemic H1N1 and a seasonal H3N2. J Bioterr Biodef 2(1):1–6. doi:10.​4172/​2157-2526.​1000104 CrossRef
6.
7.
go back to reference Fukushi S, Tani H, Yoshikawa T, Sajio M, Morikawa S (2012) Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers. Viruses 4(10):2097–2114. doi:10.3390/v4102097 Fukushi S, Tani H, Yoshikawa T, Sajio M, Morikawa S (2012) Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers. Viruses 4(10):2097–2114. doi:10.​3390/​v4102097
8.
go back to reference Fukushi S, Mizutani T, Saijo M, Matsuyama S, Miyajima N, Taguchi F, Itamura S, Kurane I, Morikawa S (2005) Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J Gen Virol 86:2269–2274. doi:10.1099/vir.0.80955-0 PubMedCrossRef Fukushi S, Mizutani T, Saijo M, Matsuyama S, Miyajima N, Taguchi F, Itamura S, Kurane I, Morikawa S (2005) Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J Gen Virol 86:2269–2274. doi:10.​1099/​vir.​0.​80955-0 PubMedCrossRef
9.
10.
go back to reference Kushch AA, Klimova RR, Masalova OV, Fedorova NE, Botikov AG, Fedyakina IT, Burtseva EI, Isaeva EI, Deryabin PG, L`vov DK (2008) Production and properties of monoclonal antibodies to a highly pathogenic strain of avian influenza virus A(H5N1) isolated in Russia. Vopr Virusol 53(5):9–14 (in Russian)PubMed Kushch AA, Klimova RR, Masalova OV, Fedorova NE, Botikov AG, Fedyakina IT, Burtseva EI, Isaeva EI, Deryabin PG, L`vov DK (2008) Production and properties of monoclonal antibodies to a highly pathogenic strain of avian influenza virus A(H5N1) isolated in Russia. Vopr Virusol 53(5):9–14 (in Russian)PubMed
11.
go back to reference Roth MG, Compans RW (1981) Delayed appearance of pseudotypes between vesicular stomatitis virus and influenza virus during mixed infection of MDCK cells. J Virol 40(3):848–860PubMedPubMedCentral Roth MG, Compans RW (1981) Delayed appearance of pseudotypes between vesicular stomatitis virus and influenza virus during mixed infection of MDCK cells. J Virol 40(3):848–860PubMedPubMedCentral
12.
go back to reference Kretzschmar E, Buonocore L, Schnell MJ, Rose JK (1997) High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J Virol 71(8):5982–5989PubMedPubMedCentral Kretzschmar E, Buonocore L, Schnell MJ, Rose JK (1997) High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J Virol 71(8):5982–5989PubMedPubMedCentral
13.
go back to reference Kalhoro NH, Veits J, Rautenschlein S, Zimmer G (2009) A recombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1). Vaccine 27(8):1174–1183PubMedCrossRef Kalhoro NH, Veits J, Rautenschlein S, Zimmer G (2009) A recombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1). Vaccine 27(8):1174–1183PubMedCrossRef
14.
go back to reference Hanika A, Larisch B, Steinmann E, Schwegmann-Weßels C, Herrler G, Zimmer G (2005) Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. J Gen Virol 86:1455–1465PubMedCrossRef Hanika A, Larisch B, Steinmann E, Schwegmann-Weßels C, Herrler G, Zimmer G (2005) Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. J Gen Virol 86:1455–1465PubMedCrossRef
16.
go back to reference Wang W, Castelán-Vega JA, Jiménez-Alberto A, Vassell R, Ye Z, Weiss CD (2010) A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity. Virology 407(2):374–380. doi:10.1016/j.virol.2010.08.027 PubMedCrossRef Wang W, Castelán-Vega JA, Jiménez-Alberto A, Vassell R, Ye Z, Weiss CD (2010) A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity. Virology 407(2):374–380. doi:10.​1016/​j.​virol.​2010.​08.​027 PubMedCrossRef
17.
go back to reference Nefkens I, Garcia J-M, Ling CS, Lagarde N, Nicholls J, Tang DJ, Peiris M, Buchy P, Altmeyer R (2007) Hemagglutinin pseudotyped lentiviral particles: characterization of a new method for avian H5N1 influenza sero-diagnosis. J Clin Virol 39:27–33. doi:10.1016/j.jcv.2007.02.005 PubMedCrossRef Nefkens I, Garcia J-M, Ling CS, Lagarde N, Nicholls J, Tang DJ, Peiris M, Buchy P, Altmeyer R (2007) Hemagglutinin pseudotyped lentiviral particles: characterization of a new method for avian H5N1 influenza sero-diagnosis. J Clin Virol 39:27–33. doi:10.​1016/​j.​jcv.​2007.​02.​005 PubMedCrossRef
18.
go back to reference Tisoncik-Go J, Cordero KS, Rong L (2013) Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system. Virol Sin 28(2):081–091CrossRef Tisoncik-Go J, Cordero KS, Rong L (2013) Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system. Virol Sin 28(2):081–091CrossRef
Metadata
Title
A vesicular stomatitis pseudovirus expressing the surface glycoproteins of influenza A virus
Authors
S. V. Cheresiz
A. A. Kononova
Yu. V. Razumova
T. S. Dubich
A. A. Chepurnov
A. A. Kushch
R. Davey
A. G. Pokrovsky
Publication date
01-10-2014
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 10/2014
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-014-2127-y

Other articles of this Issue 10/2014

Archives of Virology 10/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine